FDA Grants VAI Status to Biocon’s Biologics Facilities, Reflecting Compliance
Biocon’s Bengaluru site earns FDA's VAI status after inspection, signaling compliance with minor observations.
The U.S. FDA has classified Biocon Biologics' facilities at Biocon Park in Bengaluru, India, as "Voluntary Action Indicated" (VAI) after conducting a thorough cGMP and Pre-Licensing Inspection (PLI) in July 2024. This inspection covered multiple biologics manufacturing units, including four drug substance and two drug product plants, as well as multiple quality control and microbiology laboratories and warehouses.
The VAI status indicates that, while minor observations were noted, they do not require further regulatory action by the FDA. Biocon Biologics reaffirmed its dedication to meeting global quality and compliance standards across its operations.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Más de Pharma News
Todos los artículos →
Curia New York recibe una carta de advertencia de la FDA por miles de inyecciones cromatográficas no documentadas
Ab Science revisa los cronogramas de los ensayos tras tres inspecciones GCP
Discussion